Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 2:43 AM
Ignite Modification Date: 2025-12-26 @ 1:23 AM
NCT ID: NCT02971033
Description: there were no patients randomized to the 40mg/day ezetimibe arm
Frequency Threshold: 0
Time Frame: 12 weeks
Study: NCT02971033
Study Brief: Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Placebo placebo Placebo: Participants assigned to this intervention will receive placebo every day for 8 weeks 0 None 0 1 0 1 View
20mg/Day Ezetimibe 20mg/day ezetimibe 20mg ezetimibe: Participants assigned to this intervention will receive 20mg per day of ezetimibe for 8 weeks. 0 None 0 1 0 1 View
40mg/Day Ezetimibe 40mg/day ezetimibe 40mg ezetimibe: Participants assigned to this intervention will receive 40mg per day of ezetimibe for 8 weeks. 0 None 0 0 0 0 View
Serious Events(If Any):
Other Events(If Any):